Multiple Myeloma Hub

During the European Hematology Association (EHA) 2026 Congress, June 11–14, 2026, Stockholm, SE, the Multiple Myeloma Hub spoke with Binod Dhakal, Medical College of Wisconsin, Milwaukee, US. We asked, What are the latest findings from the phase I CaMMouflage trial evaluating CB-011 in RRMM? This educational resource is independently supported by Caribou Biosciences. All content is developed by SE...

During the Multiple Myeloma Hub Steering Committee Meeting on May 12, 2026, key opinion leaders met to discuss the integration of B-cell maturation antigen (BCMA)-directed bispecific antibodies (BsAbs) into the treatment paradigm for multiple myeloma. The discussion was led by Miles Prince (Peter MacCallum Cancer Centre, Melbourne, AU) and explored key considerations for patient selection, treatme...

During the Multiple Myeloma Hub Steering Committee Meeting on May 12, 2026, key opinion leaders met to discuss strategies for managing belantamab mafodotin-associated ocular toxicities in patients with multiple myeloma (MM). The meeting featured a presentation by guest speaker Lisa Leypoldt, University Medical Center Hamburg-Eppendorf, followed by a faculty discussion on the practical challenges o...

During the European Hematology Association (EHA) 2026 Congress, June 11–14, 2026, Stockholm, SE, the Multiple Myeloma Hub spoke with Vania Tietsche de Moraes Hungria, Clínica São Germano, São Paolo, BR. We asked, What are the updated 4-year results from the phase III DREAMM-7 trial in RRMM? This educational resource is independently supported by GSK. All content is developed by SES in collaboratio...

The Multiple Myeloma Hub spoke with Sagar Lonial, Winship Cancer Institute of Emory University, Atlanta, US. We asked, What’s on the horizon for the treatment of relapsed/refractory multiple myeloma (MM) in 2026? In this interview, Lonial provides an overview of recent and emerging developments in relapsed/refractory MM, highlighting advances in immune-based therapies and their potential to improv...

The Multiple Myeloma Hub spoke with Paul Richardson, Dana-Farber Cancer Institute, Boston, US. We asked about the emerging role of cereblon E3 ligase modulators (CELMoDs) in newly diagnosed multiple myeloma (NDMM) and high-risk smoldering multiple myeloma. During this interview, Richardson discusses the use of CELMoDs, particularly iberdomide, in earlier lines of therapy. Richardson reviews clinic...

The Multiple Myeloma Hub spoke with Paul Richardson, Dana-Farber Cancer Institute, Boston, US. We asked about cereblon E3 ligase modulators (CELMoDs) for the treatment of relapsed/refractory multiple myeloma (RRMM). During this interview, Richardson reviews clinical data on the activity of CELMoDs, including mezigdomide and iberdomide, in RRMM. Richardson highlights response rates observed in ongo...

The Multiple Myeloma Hub spoke with Paul Richardson, Dana-Farber Cancer Institute, Boston, US. We asked about the mechanism of action and immunomodulatory activity of cereblon E3 ligase modulators (CELMoDs) in multiple myeloma. During this interview, Richardson discusses how CELMoDs target the cereblon E3 ubiquitin ligase complex to induce selective protein degradation and immunomodulatory effects...

On March 5, 2026, the Multiple Myeloma Hub held a virtual symposium, titled Optimizing dosing of BCMA-directed therapies for improved quality of life in multiple myeloma. During the symposium, Rakesh Popat chaired a panel discussion featuring patient representative Lynn Williams, alongside faculty members Fredrik Schjesvold and Hang Quach, on real-world experience with belantamab mafodotin in mult...

On March 5, 2026, the Multiple Myeloma Hub held a virtual symposium, titled Optimizing dosing of BCMA-directed therapies for improved quality of life in multiple myeloma. During the symposium, Hang Quach, St Vincent’s Hospital Melbourne and University of Melbourne, Melbourne, AU, delivered a presentation on optimizing dosing strategies for B-cell maturation antigen (BCMA)-directed therapies in mul...

On March 5, 2026, the Multiple Myeloma Hub held a virtual symposium, titled Optimizing dosing of BCMA-directed therapies for improved quality of life in multiple myeloma. During the symposium, Fredrik Schjesvold, Oslo University Hospital, Oslo, NO, provided an overview of B-cell maturation antigen (BCMA)-directed therapies in multiple myeloma (MM). During this presentation, Schjesvold provides an...

On March 5, 2026, the Multiple Myeloma Hub held a virtual symposium, titled Optimizing dosing of BCMA-directed therapies for improved quality of life in multiple myeloma. During the symposium, Rakesh Popat, University College Hospital, London, UK, delivered a presentation on quality-of-life (QoL) considerations with B-cell maturation antigen (BCMA)-directed therapies in multiple myeloma...

On December 17, 2025, the Multiple Myeloma Hub held a virtual symposium, titled Integrating novel BCMA-directed therapies into clinical practice: Insights from real-world experience. During the symposium, the panel, chaired by Hermann Einsele, discussed the practical considerations when sequencing novel agents and managing adverse events with B-cell maturation antigen (BCMA)-directed therapies in...

On December 17, 2025, the Multiple Myeloma Hub held a virtual symposium, titled Integrating novel BCMA-directed therapies into clinical practice: Insights from real-world experience. During the symposium, Maria Victoria Mateos provided an overview of the potential future directions with novel and established B-cell maturation antigen (BCMA)-directed therapies in the multiple myeloma (MM) treatment...

On December 17, 2025, the Multiple Myeloma Hub held a virtual symposium, titled Integrating novel B-cell maturation antigen (BCMA)-directed therapies into clinical practice: Insights from real-world experience. During the symposium, Gordon Cook, University of Leeds, UK, delivered a presentation covering real-world insights and clinical experience with BCMA-directed therapies. In this presentation,...

On December 17, 2025, the Multiple Myeloma Hub held a virtual symposium, titled Integrating novel B-cell maturation antigen (BCMA)-directed therapies into clinical practice: Insights from real-world experience. During the symposium, Marc-Andrea Bärtsch, Heidelberg University Hospital, DE, delivered a presentation on the current applications of BCMA-directed therapies in multiple myeloma (MM) and t...

The Multiple Myeloma Hub spoke with Mehmet Hakan Kocoglu, University of Maryland, Baltimore, US. We asked, What are the latest updates from the phase I trial of P-BCMA-ALLO1 for RRMM? In this interview, Mehmet Hakan Kocoglu discussed the latest updates from the phase I trial of P-BCMA-ALLO1 for RRMM, focusing on the key efficacy and safety data for this allogeneic BCMA-directed CAR T-cell therapy....

During the Multiple Myeloma Hub Steering Committee Meeting in November 2025, key opinion leaders met to discuss improving access to chimeric antigen receptor (CAR) T-cell therapy for eligible patients with multiple myeloma. The meeting opened with a presentation by Sagar Lonial and featured a discussion including Morie Gertz, Elena Zamagni, Meral Beksaç, and Sonia Zweegmann. During his presentatio...

During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the Multiple Myeloma Hub was pleased to speak with Luciano Costa, University of Alabama at Birmingham, Birmingham, US. We asked about the long-term PFS outcomes with ciltacabtagene autoleucel (cilta-cel) for standard-risk relapsed/refractory multiple myeloma (RRMM) from the CARTITUD...

The Multiple Myeloma Hub spoke with Rakesh Popat, University College Hospital, London, UK. We asked about clinical experience with belantamab mafodotin, with a focus on strategies for managing ocular toxicity. During this interview, Popat discussed clinical experience using belantamab mafodotin for patients with relapsed or refractory multiple myeloma (RRMM), highlighting its mechanism as a B-cell...

The Multiple Myeloma Hub spoke with Paul Richardson, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, Massachusetts, US. We asked about the clinical implications of findings from the phase III MIDAS trial (NCT04934475), which evaluated a measurable residual disease (MRD)-driven consolidation and maintenance strategy after induction with isatuximab + carfilzomib + lenali...

The Multiple Myeloma Hub spoke with Paul Richardson, Dana-Farber Cancer Institute, Boston, US. We asked, How might the clinical development of cereblon E3 ligase modulators (CELMoDs) impact the treatment paradigm for multiple myeloma (MM)? During this interview, Paul Richardson discussed the emerging role of CELMoDs in MM. Richardson reviewed the rationale for the development of these agents, what...

The Multiple Myeloma Hub spoke with María-Victoria Mateos, University Hospital of Salamanca, ES. We asked about the latest findings from the updated follow-up of CARTITUDE-2 Cohort D. During this interview, Mateos discussed the latest outcomes from the phase II CARTITUDE-2, multicohort study evaluating ciltacabtagene autoleucel (Cilta-cel) across various clinical settings of unmet need. She covere...

The Multiple Myeloma Hub spoke with María-Victoria Mateos, University Hospital of Salamanca, Salamanca, Spain. We asked about the evolving diagnostic criteria for high-risk smoldering MM. During this interview, Mateos discussed the latest updates in the diagnosis, prognosis, and management of high-risk smoldering MM. The discussion covered the diagnostic criteria that distinguish smoldering MM fro...

The Multiple Myeloma Hub spoke with Ravi Vij, Washington University, St. Louis, US. We asked, What combination regimens including bispecific T-cell engagers (BiTEs) are being evaluated for the treatment of relapsed/refractory multiple myeloma (RRMM)?   During this interview, Ravi Vij discussed combination strategies involving BiTEs for the treatment of RRMM. Vij highlighted the movement...